Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-812-1 | CAS number: 593-84-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No toxicokinetic studies are available for Guanidine Thiocyanate. Assessment is based on available acute toxicity data and physicochemical properties and is developed with the aid of ECHA guidance on information requirements and chemical safety assessment chapter R7c.
Guanidine Thiocyanate is soluble in water (1562 g/L) and has a log P value of <-1.5, therefore absorption has to be expected. After oral exposure signs of systemic toxicity including death were observed in an acute toxicity study, thus absorption of Guanidine Thiocyanate has obviously occurred.
In this study clear signs of the central nervous/neuromuscular system were observed, which indicate that the substance has been distributed to the CNS. Further acute toxicity data are not available for Guanidine Thiocyanate.
As a consequence of absorption after oral exposure it is likely that the substance will also be absorbed if it is inhaled. This assumption is supported by read-across data from an acute toxicity study by inhalation route with Guanidine Hydrochloride, were systemic effects were observed.
The stratum corneum provides its greatest barrier function against hydrophilic compounds. If water solubility is above 10,000 mg/L and the log P value below 0 the substance may be too hydrophilic to cross the lipid rich environment of the stratum corneum (refer to TGD R7c).
Based on physico-chemical properties dermal uptake of Guanidine Thiocyanate is expected to be low, due to the water solubility of 1562 g/L and the log P value of <-1.5. However, Guanidine Thiocyanate is corrosive and damage to the skin surface may enhance penetration. Therefore for safety assessment the dermal absorption of corrosive concentrations is presumed to be 100 %, which pose a worst-case.
The excretion route is expected to be via the urine, because Guanidine Thiocyanate dissociates in body fluids into the corresponding ions, is highly water soluble and has a low molecular weight of 118 g/mol.
Guanidine hydrochloride is used as pharmaceutical. According to prescribing information:
“Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.” The clinical pharmacology is described as follows: “Guanidine apparently acts by enhancing the release of acetylcholine following a nerve impulse. It also appears to slow the rates of depolarization and repolarization of muscle cell membranes.” 1
The Thiocyanate ion is rapidly and almost completely absorbed, with wide extracellular distribution. Excretion is primarily via urine. Small amounts are excreted in expired air and faeces. Thiocyanate is secreted via mammary and salivary glands and gastric mucosa, where it serves as a substrate for peroxidase in milk, saliva and gastric juice. Elimination half-life is 3 days.2
“Thiocyanate is a potent inhibitor of iodide transport and is a competitive substrate for the thyroid peroxidase, but it does not appear to be concentrated in the thyroid. Blockage of the iodide trapping mechanism has a disruptive effect on the thyroid-pituitary axis, similar to iodine deficiency. The blood levels of T4 and T3 decrease, resulting in a compensatory increase in the secretion of TSH by the pituitary gland. The hypertrophy and hyperplasia of follicular cells following sustained exposure results in an increased thyroid weight and the development of goiter.“3
According to information from substance evaluation of Ammonium Thiocyanate ”…thiocyanates do not impair the activities of the thyroid gland itself. Thiocyanates only reduce the entry of iodide ions into the thyroid gland via competitive anion inhibition. In this manner, the subsequent reaction chain is limited due to lack of iodine compounds (including lack of hormones T3 and T4). However, thiocyanates do not directly affect these reactions neither enter into them nor block them. The only consequence is a limited intake of iodine. From the foregoing it can be concluded that the actual activity of the thyroid gland is not affected by thiocyanates, so from this point of view it is not an endocrine disrupting effect according to the definition of WHO(1). The eMSCA concludes that based on the available information, the concern for endocrine disruption is not confirmed.”4
References:
1. GUANIDINE HYDROCHLORIDE Tablets, Merck & Co., INC, 2015;
available at: https://www.merck.com/product/usa/pi_circulars/g/guanidine_hydrochloride/guanidine_pi.pdf
2. EFSA, Conclusion on the peer review of the pesticide risk assessment of the active substance potassium thiocyanate, EFSA Journal 2013;11(6):2922
available at: http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.2922/epdf
3. Handbook of Toxicologic Pathology,Wanda M. Haschek, Colin G. Rousseaux, 2013
4. Substance Evaluation Conclusion document Ammonium Thiocyanate, 01 August 2016, Evaluating Member State(s): Czech Republic, EC No. 217-175-6,
available at: https://echa.europa.eu/documents/10162/58ca02ce-e82b-4ea2-8e18-73ee35858391
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.